NCT06716216View on ClinicalTrials.gov

A Study of BGM0504 in Participants with Type 2 Diabetes

PHASE3RecruitingINTERVENTIONAL
Enrollment

537

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

March 20, 2026

Study Completion Date

November 14, 2026

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Drug: 5 mg BGM0504 Administered SC

Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

DRUG

Drug:10 mg BGM0504 Administered SC

Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

DRUG

Drug: Semaglutide Administered SC

"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

INDUSTRY

lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY